Mouse anti Influenza A antibody, clone 1331, recognizes the nucleoprotein of Influenza A. It has been found reactive with over 50 isolates from H1 through to H14 and gives 'nuclear' staining in immunofluorescence.
- Target Species
- Product Form
- Purified IgG - liquid
- Purified IgG prepared by affinity chromatography on Protein A
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
- Influenza virus from Texas strain.
- Approx. Protein Concentrations
- 1.0 mg/ml
- Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
- 18 months from date of despatch.
- GO Terms
structural molecule activity
host cell nucleus
interspecies interaction between organisms
- For research purposes only
This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
Applications of Influenza A antibody
|Immunohistology - Frozen
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using the appropriate negative/positive controls.
Copyright © 2020 Bio-Rad Antibodies (formerly AbD Serotec)
Secondary Antibodies Available
Application Based External Images
Product Specific References
References for Influenza A antibody
Leibbrandt, A. et al. (2010) Iota-carrageenan is a potent inhibitor of influenza A virus infection.
PLoS One. 5: e14320.
Nakayama, M. et al. (2016) Vaccination against H9N2 avian influenza virus reduces bronchus-associated lymphoid tissue formation in cynomolgus macaques after intranasal virus challenge infection.
Pathol Int. 66 (12): 678-86.